How to diagnose a lipodystrophy syndrome

Annales d'Endocrinologie

Volumn 73, Issue 3, 2012, Pages 170-189

  Vantyghem, Marie Christine ^a   Balavoine, Anne Sophie ^a   Douillard, Claire ^a   Defrance, Frédérique ^a,b   Dieudonne, Lucile ^c   Mouton, Fanny ^a,d   Lemaire, Christine ^b   Bertrand Escouflaire, Nicole ^a   Bourdelle Hego, Marie Françoise ^a   Devemy, Fabrice ^e   Evrard, Anne ^f   Gheerbrand, Dominique ^g   Girardot, Caroline ^h   Gumuche, Sophie ^a   Hober, Christine ^c   Topolinski, Hélène ^c   Lamblin, Blandine ⁱ   Mycinski, Bénédicte ^j   Ryndak, Amélie ^a   Karrouz, Wassila ^a   Duvivier, Etienne ^k   Merlen, Emilie ^a   Cortet, Christine ^a   Weill, Jacques ^a   Lacroix, Dominique ^a   Wémeau, Jean Louis ^a   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Centre Hospitalier de Béthune   (France)

^c Service des Urgences   (France)

^d CENTRE HOSPITALIER DE DOUAI   (France)

^e Centre Hospitalier de LENS   (France)

^f Polyclinique de Riaumont   (France)

^g Polyclinique de Bois Bernard ^*  (France)

^h Hôpital Privé de la Louvière   (France)

ⁱ Clinique du Parc   (France)

^j Centre Hospitalier de Calais   (France)

^k Grand Hopital de Charleroi   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; GLUCOCORTICOID; INSULIN; INTERLEUKIN 6; MITOCHONDRIAL DNA; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B BETA; PROTEINASE INHIBITOR; RECOMBINANT LEPTIN; TESAMORELIN;

ADIPOSE TISSUE; ADIPOSIS DOLOROSA; BROWN ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FAMILIAL PARTIAL LIPODYSTROPHY; FEVER; GENE MUTATION; GLYCOSYLATION; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LAMINOPATHY; LIPODYSTROPHY; LIPOMATOSIS; MARFAN SYNDROME; METABOLIC SYNDROME X; MUSCLE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PANNICULITIS; PATHOPHYSIOLOGY; POLYMYOSITIS; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; SHORT SURVEY; SKIN DISEASE; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADIPOGENESIS; ADIPOKINES; ADIPOSE TISSUE; ANTI-HIV AGENTS; CARDIOMYOPATHIES; GENES, RECESSIVE; HUMANS; INSULIN RESISTANCE; LEPTIN; LIPODYSTROPHY; LIPOMATOSIS; MAGNETIC RESONANCE IMAGING; METABOLIC SYNDROME X; MUTATION; PHYSICAL EXAMINATION; SKIN; SYNDROME;

EID: 84863819003     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2012.04.010     Document Type: Short Survey

References (82)

1. Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 2011, 96:3313-3325.
2. Herrero L., Shapiro H., Nayer A., Lee J., Shoelson SE Inflammation and adipose tissue macrophages in lipodystrophic mice. Proc Natl Acad Sci U S A 2010, 107:240-245.
3. Spite M., Hellmann J., Tang Y., Mathis S.P., Kosuri M., Bhatnagar A., et al. Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. J Immunol 2011, 187:1942-1949.
4. Couturier J., Patel S.G., Iyer D., Balasubramanyam A., Lewis D.E. Human monocytes accelerate proliferation and blunt differentiation of preadipocytes in association with suppression of C/EBPA mRNA. Obesity (Silver Spring) 2012, 20:253-262.
5. Bouloumié A., Casteilla L., Lafontan M. Adipose tissue lymphocytes and macrophages in obesity and insulin resistance: makers or markers, and which comes first?. Arterioscler Thromb Vasc Biol 2008, 28:1211-1213.
6. Hamilton G., Smith D.L., Bydder M., Nayak K.S., Hu H.H. MR properties of brown and white adipose tissues. J Magn Reson Imaging 2011, 34:468-473.
7. Lee P., Swarbrick M.M., Zhao J.T., Ho K.K. Inducible brown adipogenesis of supraclavicular fat in adult humans. Endocrinology 2011, 152:3597-3602.
8. Béréziat V., Cervera P., Le Dour C., Verpont M.C., Dumont S., Vantyghem M.C., et al. LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue. Am J Pathol 2011, 179:2443-2453.
9. Seale P., Conroe H.M., Estall J., Kajimura S., Frontini A., Ishibashi J., et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest 2011, 121:96-105.
10. Jing E., Emanuelli B., Hirschey M.D., Boucher J., Lee K.Y., Lombard D., et al. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc Natl Acad Sci U S A 2011, 108:14608-14613.
11. Kulkarni S.S., Karlsson H.K., Szekeres F., Chibalin A.V., Krook A., Zierath J.R. Suppression of 5'- nucleotidase enzymes promotes AMP-activated protein kinase (AMPK) phosphorylation and metabolism in human and mouse skeletal muscle. J Biol Chem 2011, 286:34567-34574.
12. Amati F., Dubé J.J., Alvarez-Carnero E., Edreira M.M., Chomentowski P., Coen P.M., et al. Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes?. Diabetes 2011, 60:2588-2597.
13. Gandotra S., Le Dour C., Bottomley W., Cervera P., Giral P., Reznik Y., et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med 2011, 364:740-748.
14. Vigouroux C., Magre J., Vantyghem Mc, Bourut C., Lascols O., Schackleton S., et al. Lamin A/C gene: sex-determined expression of mutations in Dunniga-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes 2000, 49:1958-1962.
15. Decaudain A., Vantyghem Mc, Guerci B., Hecart Ac, Reznik Y., Narbonne H., et al. New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. J Clin Endocrinol Metab 2007, 92:4835-4844.
16. Vantyghem Mc, Pigny P., Maurage N., Rouaix-Emery N., Stojkovic T., Cuisset Jm, et al. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J Clin Endocrinol Metab 2004, 89:5337-5346.
17. Llamas-Velasco M., Daudén E., Martínez-Peñas G., García-Diez A. Late-onset acquired generalized lipodystrophy with muscle involvement. Actas Dermosifiliogr 2011, [Epub ahead of print].
18. Saini-Chohan H.K., Mitchell R.W., Vaz F.M., Zelinski T., Hatch G.M. Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: thematic review series: genetics of human lipid diseases. J Lipid Res 2012, 53:4-27.
19. Caux F., Dubosclard E., Lascols O., Buendia B., Chazouillères O., Cohen A., et al. A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leuko-melano-dermic papules, liver steatosis, and cardiomyopathy. J Clin Endocrinol Metab 2003, 88:1006-1013.
20. Madej-Pilarczyk A., Rosińska-Borkowska D., Rekawek J., Marchel M., Szaluś E., Jabłońska S., et al. Progeroid syndrome with scleroderma-like skin changes associated with homozygous R435C LMNA mutation. Am J Med Genet A 2009, 149A:2387-2392.
21. Sagelius H., Rosengardten Y., Hanif M., Erdos M.R., Rozell B., Collins F.S., et al. Targeted transgenic expression of the mutation causing Hutchinson-Gilford progeria syndrome leads to proliferative and degenerative epidermal disease. J Cell Sci 2008, 121(Pt 7):969-978.
22. McKeon F.D., Tuffanelli D.L., Fukuyama K., Kirschner M.W. Autoimmune response directed against conserved determinants of nuclear envelope proteins in a patient with linear scleroderma. Proc Natl Acad Sci U S A 1983, 80:4374-4378.
23. Lungu A.O., Safar Zadeh E., Goodling A., Cochran E., Gorden P. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2012, 97:563-567.
24. Vantyghem Mc, Vincent-Desplanques D., Defrance-Faivre F., Capeau J., Fermon C., Valat As, et al. Fertility and obstetrical complications in women with lmna-related familial partial lipodystrophy. J Clin Endocrinol Metab 2008, 93:2223-2229.
25. Lupsa B.C., Sachdev V., Lungu A.O., Rosing D.R., Gorden P. Cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment. Medicine (Baltimore) 2010, 89:245-250.
26. Vantyghem M.C., Faivre-Defrance F., Vincent-Desplanque D., Fermon C., Pattou F., Evrard A., et al. Familial partial lipodystrophic syndrome with multinodular goiter, extrapyramidal syndrome and primary hyperaldosteronism: comparison with lmna-mutated lipodystrophic and non-mutated family controls. Clin Endocrinol 2007, 67:247-249.
27. Ito D., Suzuki N. Seipinopathy: a novel endoplasmic reticulum stress-associated disease. Brain 2009, 132(Pt 1):8-15.
28. Vantyghem M.C., Dieudonné L., Wolowczuk L'interleukine 7: un senseur du rapport graisse viscérale/totale dans les syndromes lipodystrophiques ? Communication orale Société française d'endocrinologie. Ann Endocrinol 2011, 5:347-348. (abstract).
29. Wong S.P., Huda M., English P., Bargiotta A., Wilding J.P., Johnson A., et al. Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. Diabetologia 2005, 48:2641-2649.
30. Veloso S., Escoté X., Ceperuelo-Mallafré V., López-Dupla M., Peraire J., Viladés C., et al. Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy. Cytokine 2012, 58:253-260.
31. Al-Attar S.A., Pollex R.L., Robinson J.F., Miskie B.A., Walcarius R., Rutt B.K., et al. Semiautomated segmentation and quantification of adipose tissue in calf and thigh by MRI: a preliminary study in patients with monogenic metabolic syndrome. BMC Med Imaging 2006, 6:11.
32. Sankar J., Mohan G., Pariyarath R., Verghese J. Visceral fat assessment in over nourished children by ultrasonography and its relation to anthropometry. Indian J Pediatr 2012, [Epub ahead of print].
33. Rzymski P., Wysocki P.J., Kycler W., Opala T. Correlation between insulin resistance and breast elasticity heterogeneity measured by shear wave elastography in premenopausal women - a pilot study. Arch Med Sci 2011, 7:1017-1022.
34. Sysi-Aho M., Koikkalainen J., Seppänen-Laakso T., Kaartinen M., Kuusisto J., Peuhkurinen K., et al. Serum lipidomics meets cardiac magnetic resonance imaging: profiling of subjects at risk of dilated cardiomyopathy. PLoS One 2011, 6:e15744.
35. Spuler S., Kalbhenn T., Zabojszcza J., van Landeghem F.K., Ludtke A., Wenzel K., et al. Muscle and nerve pathology in Dunnigan familial partial lipodystrophy. Neurology 2007, 68:677-683.
36. Duband-Goulet I., Woerner S., Gasparini S., Attanda W., Kondé E., Tellier-Lebègue C., et al. Subcellular localization of SREBP1 depends on its interaction with the C-terminal region of wild-type and disease related A-type lamins. Exp Cell Res 2011, 317:2800-2813.
37. Le Dour C., Schneebeli S., Bakiri F., Darcel F., Jacquemont M.L., Maubert M.A., et al. A homozygous mutation of prelamin A preventing its farnesylation and maturation leads to a severe lipodystrophic phenotype: new insights into the pathogenicity of nonfarnesylated prelamin A. J Clin Endocrinol Metab 2011, 96:E856-E862.
38. Barrowman J., Hamblet C., Kane M.S., Michaelis S. Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24. PLoS One 2012, 7:e32120.
39. Visser M.E., Kropman E., Kranendonk M.E., Koppen A., Hamers N., Stroes E.S., et al. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy associated PPARγ mutation (Y151C). Diabetologia 2011, 54:1639-1644.
40. Tan K., Kimber W.A., Luan J., Soos M.A., Semple R.K., Wareham N.J., et al. Analysis of genetic variation in Akt2/PKB-_ in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes. Diabetes 2007, 56:714-719.
41. Rubio-Cabezas O., Puri V., Murano I., Saudek V., Semple R.K., Dash S., et al. LD screening consortium. Partial lipodystrophy and insulin-resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. Embo Mol Med 2009, 1:280-287.
42. Ben Yaou R., Navarro C., Quijano-Roy S., Bertrand A.T., Massart C., De Sandre-Giovannoli A., et al. Bonne G Type B mandibuloacral dysplasia with congenital myopathy due to homozygous ZMPSTE24 missense mutation. Eur J Hum Genet 2011, 19:647-654.
43. Pelosini C., Martinelli S., Bagattini B., Pucci E., Fierabracci P., Scartabelli G., et al. Description of an AGPAT2 pathologic allelic variant in a 54-year-old Caucasian woman with Berardinelli-Seip syndrome. Acta Diabetol 2011, 48:243-246.
44. Chen W., Chang B., Saha P., Hartig S.M., Li L., Reddy V.T., et al. Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation. Mol Cell Biol 2012, 32:1099-1111.
45. Dwianingsih E.K., Takeshima Y., Itoh K., Yamauchi Y., Awano H., Malueka R.G., et al. A Japanese child with asymptomatic elevation of serum creatine kinase shows PTRF-CAVIN mutation matching with congenital generalized lipodystrophy-type 4. Mol Genet Metab 2010, 101:233-237.
46. Briand N., Le Lay S., Sessa W.C., Ferré P., Dugail I. Distinct roles of endothelial and adipocyte caveolin-1 in macrophage infiltration and adipose tissue metabolic activity. Diabetes 2011, 60:448-453.
47. Kitamura A., Maekawa Y., Uehara H., Izumi K., Kawachi I., Nishizawa M., et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest 2011, 121:4150-4160.
48. Goldbach-Mansky R. Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 2012, 167:391-404.
49. Casado M., O'Callaghan M.M., Montero R., Pérez-Cerda C., Pérez B., Briones P., et al. Mild clinical and biochemical phenotype in two patients with PMM2-CDG (Congenital Disorder of Glycosylation Ia). Cerebellum 2011, 11:557-563.
50. Horn D., Robinson PN Progeroid facial features and lipodystrophy associated with a novel splice site mutation in the final intron of the FBN1 gene. Am J Med Genet A 2011, 155A:721-724.
51. Cabanillas R., Cadiñanos J., Villameytide J.A., Pérez M., Longo J., Richard J.M., et al. Néstor-Guillermo progeria syndrome: a novel premature aging condition with early onset and chronic development caused by BANF1 mutations. Am J Med Genet A 2011, 155A:2617-2625.
52. Capeau J., Bouteloup V., Katlama C., Bastard J.P., Guiyedi V., Salmon-Ceron D., et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012, 26:303-314.
53. Boufassa F., Goujard C., Viard J.P., Carlier R., Lefebvre B., Yeni P., et al. Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. Antivir Ther 2012, 17:91-100.
54. Fardet L., Antuna-Puente B., Vatier C., Cervera P., Touati A., Simon T., et al. Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy. Clin Endocrinol (Oxf) 2012, [Epub ahead of print]. 10.1111/j.1365-2265.2012.04348.x.
55. Milan G., Murano I., Costa S., Pianta A., Tiengo C., Zulato E., et al. Lipoatrophy induced by subcutaneous insulin infusion: ultrastructural analysis and gene expression profiling. J Clin Endocrinol Metab 2010, 95:3126-3132.
56. Livadas S, Voutetakis A, Bourhis JC, Maratou E, Dimitriadis G, Margeli A, et al. Severe hyperinsulinemia, decreased GLUT3 and GLUT4 expression, and increased retinol binding protein 4 in a patient with chronic graft-versus-host disease post-bone marrow transplantation. Pediatr Transplant 2011. [Epub ahead of print]. doi:10.1111/j.1399-3046.2011.01562.x.
57. Bingham A., Mamyrova G., Rother K.I., Oral E., Cochran E., Premkumar A., et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008, 87:70-86.
58. Mathiesen P., Hegaard H., Herlin T., Zak M., Pedersen F., Nielsen S. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 2012, 41:50-58.
59. Misra A., Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore) 2003, 82:129-146.
60. Hegele R.A., Cao H., Liu D.M., Costain G.A., Charlton-Menys V., Rodger N.W., et al. Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am J Hum Genet 2006, 79:383-389.
61. Park J.Y., Chong A.Y., Cochran E.K., Kleiner D.E., Haller M.J., Schatz D.A., et al. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab 2008, 93:26-31.
62. Savage D.B., Semple R.K., Clatworthy M.R., Lyons P.A., Morgan B.P., Cochran E.K., et al. Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab 2009, 94:10-16.
63. Herbst K.L., Tannock L.R., Deeb S.S., Purnell J.Q., Brunzell J.D., Chait A. Köbberling type of familial partial lipodystrophy: an under-recognized syndrome. Diabetes Care 2003, 26:1819-1824.
64. Ampollini L., Carbognani P. Images in clinical medicine. Madelung's disease. N Engl J Med 2011, 364:465.
65. Sokolov M., Mendes D., Ophir D. Madelung's disease. Isr Med Assoc J 2010, 12:253-254.
66. Kobayashi J., Nagao M., Miyamoto K., Matsubara S. MERRF syndrome presenting with multiple symmetric lipomatosis in a Japanese patient. Intern Med 2010, 49:479-482.
67. Hu M., Wang F., Li X., Rogers C.Q., Liang X., Finck B.N., et al. Regulation of hepatic lipin-1 by ethanol: role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice. Hepatology 2012, 55:437-446.
68. Yin H., Hu M., Zhang R., Shen Z., Flatow L., You M. MiR-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem 2012, 287:9817-9826.
69. Herbst K.L., Coviello A.D., Chang A., Boyle D.L. Lipomatosis associated inflammation and excess collagen may contribute to lower relative resting energy expenditure in women with adiposis dolorosa. Int J Obes (Lond) 2009, 33:1031-1038.
70. Yee J.K., Phillips S.A., Allamehzadeh K., Herbst K.L. Subcutaneous adipose tissue fatty acid desaturation in adults with and without rare adipose disorders. Lipids Health Dis 2012, 11:19.
71. Fiorenza C.G., Chou S.H., Mantzoros C.S. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol 2011, 7:137-150.
72. Vantyghem M.C., Vigouroux C., Magré J., Desbois-Mouthon C., Pattou F., Fontaine P., et al. Late-onset lipoatrophic diabetes. Phenotypic and genotypic familial studies and effect of treatment with metformin and lispro insulin analog. Diabetes Care 1999, 22:1374-1376.
73. Moreau F., Boullu-Sanchis S., Vigouroux C., Lucescu C., Lascols O., Sapin R., et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab 2007, 33:385-389.
74. Luedtke A., Boschmann M., Colpe C., Engeli S., Adams F., Birkenfeld A.L., et al. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series. Horm Metab Res 2012, 44:306-311.
75. Barroso E., Rodríguez-Calvo R., Serrano-Marco L., Astudillo A.M., Balsinde J., Palomer X., et al. The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation. Endocrinology 2011, 152:1848-1859.
76. Oriot P., Hermans M.P., Selvais P., Buysschaert M., de la Tribonnière X. Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. Ann Endocrinol (Paris) 2011, 72:244-246.
77. Spooner L.M., Olin J.L. Tesamorelin: a growth hormone releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother 2012, 46:240-247.
78. Simha V., Subramanyam L., Szczepaniak L., Quittner C., Adams-Huet B., Snell P., et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab 2011, 97:785-792.
79. Chan J.L., Lutz K., Cochran E., Huang W., Peters Y., Weyer C., et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract 2011, 17:922-932.
80. Peterson T.R., Sengupta S.S., Harris T.E., Carmack A.E., Kang S.A., Balderas E., et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011, 146:408-420.
81. Cenni V., Capanni C., Columbaro M., Ortolani M., D'Apice M.R., Novelli G., et al. Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria. Eur J Histochem 2011, 55:e36.
82. Xia G., Liu L., Xue M., Liu H., Yu J., Li P., et al. Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11β-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2012, 358:46-52.